Details for New Drug Application (NDA): 209512

NDA 209512 describes NORVIR, which is a drug marketed by Abbott and Abbvie and is included in five NDAs. It is available from one supplier. Additional details are available on the NORVIR profile page.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

Summary for 209512

Tradename:	NORVIR
Applicant:	Abbvie
Ingredient:	ritonavir
Patents:	0

Pharmacology for NDA: 209512

Mechanism of Action

Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inducers Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A Inducers Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors HIV Protease Inhibitors P-Glycoprotein Inhibitors UDP Glucuronosyltransferases Inducers

Medical Subject Heading (MeSH) Categories for 209512

Cytochrome P-450 CYP3A Inhibitors

HIV Protease Inhibitors

Suppliers and Packaging for NDA: 209512

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
NORVIR	ritonavir	POWDER;ORAL	209512	NDA	AbbVie Inc.	0074-3399	0074-3399-30	30 PACKET in 1 CARTON (0074-3399-30) / 1 POWDER in 1 PACKET

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	POWDER;ORAL			Strength	100MG/PACKET
Approval Date:	Jun 7, 2017	TE:		RLD:	Yes

Complete Access Available with Subscription